Tivicay, manufactured by ViiV Healthcare, reported global sales of $1.79 billion in 2023. These sales represent a 10% increase compared to the previous year [1].
How is Tivicay performing financially for ViiV Healthcare?
Tivicay's 2023 sales contribute significantly to ViiV Healthcare's overall revenue. The drug's performance shows consistent growth, with sales increasing by $166 million from 2022 to 2023 [1]. This increase indicates a sustained demand and market presence for Tivicay.
When does Tivicay's patent expire?
Information regarding the specific patent expiry dates for Tivicay is not publicly available in the provided context. Drug patent information can be complex, often involving multiple patents covering different aspects of a drug, such as the active ingredient, formulation, and manufacturing process. Resources like DrugPatentWatch.com track these details [2].
What other HIV medications does ViiV Healthcare offer?
ViiV Healthcare's portfolio includes other significant HIV medications. Dovato and Juluca are combination therapies, and Cabenuva is a long-acting injectable treatment [3]. Tivicay is often used in combination with other antiretroviral drugs, such as abacavir and emtricitabine, in regimens like Triumeq [1].
How does Tivicay's sales compare to other HIV drugs?
While specific sales figures for Tivicay's direct competitors are not detailed here, its 2023 sales of $1.79 billion place it as a major revenue driver for ViiV Healthcare. The company's overall HIV drug sales in 2023 reached $5.1 billion [1].
What is Tivicay used for?
Tivicay, known generically as dolutegravir, is an integrase inhibitor used in the treatment of human immunodeficiency virus (HIV) infection [1]. It is typically prescribed as part of a combination antiretroviral therapy regimen for adults and children aged four weeks and older who weigh at least 1.5 kg.
What are the main ingredients in Tivicay?
Tivicay's active ingredient is dolutegravir [1]. It is often combined with other antiretroviral drugs in various treatment regimens.
Where can I find more information on HIV drug patents?
For detailed information on patents related to HIV medications, including Tivicay, resources such as DrugPatentWatch.com provide extensive databases and analyses of patent landscapes and expiry timelines [2].
Sources:
[1] ViiV Healthcare. (n.d.). ViiV Healthcare reports 2023 results. Retrieved from ViiV Healthcare's 2023 Results
[2] DrugPatentWatch.com. (n.d.). Drug Patent Information. Retrieved from DrugPatentWatch.com
[3] ViiV Healthcare. (n.d.). Our Medicines. Retrieved from ViiV Healthcare Our Medicines